T/FIF, a New Plateau Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (937)	2/6/2002 11:22:15 AM
From: scaram(o)uche	Read Replies (3) of 2243

>> Frovatriptan sales are forecast to reach Dollars 250m << I feel that a long half-life triptan could do much better than this. Anecdote from a single headache victim! When I first got a prescription for Maxalt, I would have cringed at the thought of out-of-pocket expense of $8 per headache. That's the perspective of someone who has come to expect hours of rest in dark/silence/prayer to allow for marginal relief. Now, having experienced the (anecdote) "night and day" results from a triptan, I'd pay $50, no sweat. I don't know anything about the percentage of headache victims who will be helped by triptans. Maybe I'm an exception, and I've never considered mine to be classical migraines. However, Maxalt is a miracle drug for me. I expect the triptan market to explode. Frovie could be a sleeper.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next